Target Grants

Request for Proposals

Closed

Award Amount and Performance Period:

  • Type 1: Up to $100,000 direct costs, plus up to 20% indirect costs. One year duration.
  • Type 2: up to $400,000 direct costs, plus up to 20% indirect costs. Up to two years duration.

Type 1 submissions will likely have a higher funding success rate than type 2 submissions.

amfAR aims to support research projects focused on curing HIV.

Proposals should be interventional

  • The intervention can take place in any model including PWH, NHP, humanized mice, or cells. If the intervention will be tested in cell lines, a full application, if solicited, must include an in-depth justification describing why this is better than testing in primary cells or cells from PWH.
  • Submissions that propose only describing the reservoir (i.e. no intervention) will not be forwarded for review and will not be funded.
  • Specific aims that are descriptive, within a submission that includes an intervention, may be cut by amfAR if the descriptive work does not pertain to changes to the reservoir in response to the intervention.

amfAR’s preference is for interventions that eliminate infected cells or provirus, rather than those that provide for ART-free control of persisting virus.

If you are an HIV researcher holding a doctoral degree and affiliated with a nonprofit research institute, tell us:

  • what you’d like to do
  • why
  • how much it will cost, and
  • how long it will take

If it’s an idea we think might be right for us, we’ll be in touch to start talking through more specifics and, if we can find a mutually satisfactory study design, solicit a full proposal.

Send your brief synopsis to grants@amfar.org with the subject line, “Target Grants Synopsis.” We regret we are unable to discuss every submission with applicants.
If an application is solicited, it will be due in late July or early August.

Details

Background and Purpose
amfAR’s research initiatives are aimed at finding a cure for HIV that will be useful to the 38M people living with HIV. The urgency of our goal demands that we direct our funding to studies that uncover vital knowledge directly applicable to curing HIV.

Persistent reservoirs of virus not cleared by antiretroviral therapy (ART) represent the main barrier to a cure. amfAR prioritizes the development of an eradicative cure over ART-free control of persistent virus. Eradication is preferred by PWH, should obviate the need for ongoing monitoring, may result in seroreversion with its attendant benefits, and is an unambiguous improvement over treatment, including with long-acting ART. However, amfAR also recognizes the value of a cure by ART-free control of persisting virus.

An eradicative cure requires the removal of HIV proviruses, or the cells that harbor them. Although not strictly necessary, an eradicative cure that also protects individuals from reinfection is of particularly high interest.

The development of a cure will require a series of well-planned research steps. The development pipeline is commonly thought to proceed from in vitro through ex vivo and preclinical animal testing stages before proceeding to clinical trial. Applicants should be able to:

  • describe the clinical intervention they are working towards;
  • articulate the current stage of development of their product; and
  • describe the steps needed to progress to clinical testing.

Applicants may propose laboratory, animal or clinical research. Applicants should articulate a series of milestones that culminate in a clinical trial of the cure concept under consideration. Applications must be interventional, not descriptive.